Prime Medicine PRME

Prime Medicine, Inc. is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable and potentially curative treatment options for patients with diseases driven by defined genetic alterations acquired cellular dysfunction or dysregulated gene expression. Its approach relies on Prime Editing a next generation gene editing technology that enables targeted modifications to genomic DNA without creating double stranded breaks. The company targets liver directed in vivo programs for Wilson disease and alpha 1 antitrypsin deficiency an ex vivo program for chronic granulomatous disease in collaboration with Bristol Myers Squibb and early stage cystic fibrosis efforts using lipid nanoparticle or adeno associated virus delivery.

Prime Medicine generates revenue primarily through collaboration agreements licensing deals and associated milestone payments and royalties. It received a fifty five million dollar upfront payment and a fifty five million dollar equity investment from Bristol Myers Squibb under a research collaboration and license agreement and is eligible to receive more than three point five billion dollars in milestones plus royalties on net sales. The Cystic Fibrosis Foundation has committed up to fifteen million dollars under a 2024 agreement and up to twenty four million dollars under a 2025 agreement to support cystic fibrosis related programs. Additionally the company earns license maintenance fees and potential milestone and royalty payments from its agreements with the Broad Institute and Beam Therapeutics. No commercial product sales have been recorded to date.

Prime Medicine differentiates itself in the genetic medicines industry through the precision versatility modularity and improved safety profile of its Prime Editing platform compared with CRISPR nucleases base editors and RNA editing tools. Competitors include CRISPR Therapeutics Editas Medicine Intellia Therapeutics Caribou Biosciences Beam Therapeutics Verve Therapeutics Tessera Therapeutics Metagenomi Therapeutics Scribe Therapeutics Arbor Biotechnologies and RNA focused companies such as Ionis Pharmaceuticals Alnylam Pharmaceuticals Sarepta Therapeutics Wave Life Sciences and Moderna. The company believes its ability to make a broad range of genetic edits without double stranded breaks provides a competitive advantage in addressing diverse rare genetic disorders.

The company s current customers and collaborators include Bristol Myers Squibb through its subsidiary Juno Therapeutics the Cystic Fibrosis Foundation the Broad Institute for prime editing technology licenses and Beam Therapeutics via a collaboration agreement. These partners provide funding milestone payments royalties and access to complementary capabilities such as cell therapy expertise and manufacturing scale. Prime Medicine ultimately intends to serve patients suffering from rare genetic diseases once its therapies reach market.